Rational Design of Constrained Peptides As Protein Interface Inhibitors

Overview

Journal Antibodies (Basel)

Date 2021 Aug 27

PMID 34449551

Citations 1

Authors

Ramachandran Murali

Hongtao Zhang

Zheng Cai

Lian Lam

Mark Greene

Affiliations

Soon will be listed here.

Abstract

The lack of progress in developing targeted therapeutics directed at protein-protein complexes has been due to the absence of well-defined ligand-binding pockets and the extensive intermolecular contacts at the protein-protein interface. Our laboratory has developed approaches to dissect protein-protein complexes focusing on the superfamilies of erbB and tumor necrosis factor (TNF) receptors by the combined use of structural biology and computational biology to facilitate small molecule development. We present a perspective on the development and application of peptide inhibitors as well as immunoadhesins to cell surface receptors performed in our laboratory.

Citing Articles

Peptide-based allosteric inhibitor targets TNFR1 conformationally active region and disables receptor-ligand signaling complex.

Zeng J, Loi G, Saipuljumri E, Romero Duran M, Silva-Garcia O, Perez-Aguilar J Proc Natl Acad Sci U S A. 2024; 121(14):e2308132121.

PMID: 38551841 PMC: 10998571. DOI: 10.1073/pnas.2308132121.

References

Jones S, Marin A, Thornton J . Protein domain interfaces: characterization and comparison with oligomeric protein interfaces. Protein Eng. 2000; 13(2):77-82. DOI: 10.1093/protein/13.2.77. View

Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M . Synthetic therapeutic peptides: science and market. Drug Discov Today. 2009; 15(1-2):40-56. DOI: 10.1016/j.drudis.2009.10.009. View

Murali R, Greene M . Structure based antibody-like peptidomimetics. Pharmaceuticals (Basel). 2013; 5(2):209-35. PMC: 3763629. DOI: 10.3390/ph5020209. View

Vaughan C, Buckle A, Fersht A . Structural response to mutation at a protein-protein interface. J Mol Biol. 1999; 286(5):1487-506. DOI: 10.1006/jmbi.1998.2559. View

Cunningham A, Qvit N, Mochly-Rosen D . Peptides and peptidomimetics as regulators of protein-protein interactions. Curr Opin Struct Biol. 2017; 44():59-66. PMC: 5496809. DOI: 10.1016/j.sbi.2016.12.009. View

Hasegawa A, Cheng X, Kajino K, Berezov A, Murata K, Nakayama T . Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism. Proc Natl Acad Sci U S A. 2004; 101(17):6599-604. PMC: 404091. DOI: 10.1073/pnas.0401597101. View

Burley S, Berman H, Kleywegt G, Markley J, Nakamura H, Velankar S . Protein Data Bank (PDB): The Single Global Macromolecular Structure Archive. Methods Mol Biol. 2017; 1607:627-641. PMC: 5823500. DOI: 10.1007/978-1-4939-7000-1_26. View

Park B, Zhang H, Wu C, Berezov A, Zhang X, Dua R . Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat Biotechnol. 2000; 18(2):194-8. DOI: 10.1038/72651. View

Naismith J, Devine T, Kohno T, Sprang S . Structures of the extracellular domain of the type I tumor necrosis factor receptor. Structure. 1996; 4(11):1251-62. DOI: 10.1016/s0969-2126(96)00134-7. View

10.

Shendure J, Findlay G, Snyder M . Genomic Medicine-Progress, Pitfalls, and Promise. Cell. 2019; 177(1):45-57. PMC: 6531313. DOI: 10.1016/j.cell.2019.02.003. View

11.

Bhat T, Bentley G, Boulot G, Greene M, Tello D, DallAcqua W . Bound water molecules and conformational stabilization help mediate an antigen-antibody association. Proc Natl Acad Sci U S A. 1994; 91(3):1089-93. PMC: 521459. DOI: 10.1073/pnas.91.3.1089. View

12.

Makley L, Gestwicki J . Expanding the number of 'druggable' targets: non-enzymes and protein-protein interactions. Chem Biol Drug Des. 2012; 81(1):22-32. PMC: 3531880. DOI: 10.1111/cbdd.12066. View

13.

Hanack K, Messerschmidt K, Listek M . Antibodies and Selection of Monoclonal Antibodies. Adv Exp Med Biol. 2016; 917:11-22. DOI: 10.1007/978-3-319-32805-8_2. View

14.

Idress M, Milne B, Thompson G, Trembleau L, Jaspars M, Houssen W . Structure-Based Design, Synthesis and Bioactivity of a New Anti-TNFα Cyclopeptide. Molecules. 2020; 25(4). PMC: 7071015. DOI: 10.3390/molecules25040922. View

15.

Naismith J, Sprang S . Modularity in the TNF-receptor family. Trends Biochem Sci. 1998; 23(2):74-9. DOI: 10.1016/s0968-0004(97)01164-x. View

16.

Kojima T, Aoki K, Nonaka K, Saito H, Azuma M, Iwai H . Subcutaneous injections of a TNF-alpha antagonistic peptide inhibit both inflammation and bone resorption in collagen-induced murine arthritis. J Med Dent Sci. 2005; 52(1):91-9. View

17.

Sazinsky S, Ott R, Silver N, Tidor B, Ravetch J, Wittrup K . Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci U S A. 2008; 105(51):20167-72. PMC: 2629253. DOI: 10.1073/pnas.0809257105. View

18.

Kieber-Emmons T, Murali R, Greene M . Therapeutic peptides and peptidomimetics. Curr Opin Biotechnol. 1997; 8(4):435-41. DOI: 10.1016/s0958-1669(97)80065-1. View

19.

Strong R, Campbell R, Rose D, Petsko G, Sharon J, Margolies M . Three-dimensional structure of murine anti-p-azophenylarsonate Fab 36-71. 1. X-ray crystallography, site-directed mutagenesis, and modeling of the complex with hapten. Biochemistry. 1991; 30(15):3739-48. DOI: 10.1021/bi00229a022. View

20.

Sundberg E, Mariuzza R . Molecular recognition in antibody-antigen complexes. Adv Protein Chem. 2002; 61:119-60. DOI: 10.1016/s0065-3233(02)61004-6. View